Preliminary Program. 1 st, 2 nd, 3 Rd October rd edition. Cité Internationale Universitaire of Paris, France

Transcription

1 1 st, 2 nd, 3 Rd October 2012 Cité Internationale Universitaire of Paris, France 3 rd edition Preliminary Program Innovation Days 2012 Highlights Unique international partnering event in Paris Innovation showcase Early-stage licensing opportunities Cité Internationale Universitaire 27 Boulevard Jourdan Paris

2 INNOVATION DAYS PRESENTATION About the conference The Innovation Days continue the tradition of providing early-stage lifescience companies with high caliber partnering opportunities. The event enables delegates to power their network from innovative start-ups to pharma and investors. The Innovation Days are the unique place dedicated to the identification, assessment, presentation of the most innovative projects through Europe. An overview of Innovation Days 2011 More than 500 scheduled one-to-one meetings Over 550 attendees 260 companies 16 biotech presentations 40 exhibitors 18 countries represented 40 speakers, leading conferences, round tables and workshops

3 I N N O VAT I O N D AY S P R E S E N TAT I O N Innovation Days Highlights Excellent early-stage networking opportunities Selected Biotechnology companies presentations Interactive workshops and panels feature industry experts State-of-the-art partnering software International exhibition of major new products and solutions LITY INNOVATION INA ORIG STRATEGY Who will you meet? Emerging biotech companies Academic researchers and Innovation Prize candidates Pharmaceutical companies Institutional representatives Clusters and bioparks Researchers Biotech Pharma Other (CRO, Service Providers, Government, Agencies, Associations, Universities, Press...)

4 MONDAY, OCTOBER 1 st, :00 Registration and Exhibition open Continental Breakfast 9:20-9:30 Welcome and opening remarks Rafi MARDACHTI, President & CEO, Universal Medica Group 9:30-10:15 Keynote opening address The Place of Open Innovation in the Biotechnology and Healthcare Sector in 2012: Facts and Challenges The industry is clearly grappling with a significant need to change its innovation model and engage in new way of thinking. If internal R&D and external alliances remain the leading source of innovation, there is an emerging trend towards Open Innovation. The concept is being seen as an effective way to stimulate new ideas and to innovate more cost effectively. Can Open Innovation really solve pharma s productivity crisis? This high-level presentation will deliver views from various stakeholders in the innovation process in order to debate the reality of the Open Innovation Concept: The Open Innovation agenda and evidence: Has it really worked so far for Pharma? Is it making any difference in the market? Overcoming the challenges inherent in Open Innovation: Process coordination, Management of Intellectual Property, Research Costs How Pharma are applying Open Innovation in their business model? Marc DE GARIDEL, President, Ipsen Group, (FR) Olivier Charmeil, President & CEO, Sanofi Pasteur (FR) Michel GOLDMAN, Executive Director, IMI (B) Pascale Auge, Entrepreneurship & Technology Transfer Service, Institut Pasteur, (FR) 10:15-11:00 Plenary session Fostering Early-Stage Partnership Among Pharma and Academia Driven in part by the dearth of VC available for early-stage start-ups and competition for late-stage in-licensing candidates, pharma companies are turning to academic institutions to foster early stage partnerships. These collaborations can be a way to access technologies and engage with talent already at university level. Within the academic institutions, the more commercially minded see these partnerships as a way to move their programs and technologies from the bench into the clinic more efficiently. How do Pharma and Academia overcome conflicting core values, rights to IP, and co-mingling of funds to successfully manage the alliance? Is there a new drug development business model evolving that reduces the need for venture capital? This panel will explore the growing importance of Academia to the future of Pharma s R&D pipelines. Manfred Horst, Director Licensing & External Research Europe, Merck&Co (D) Patrick FAURE, Executive Director, Health and Life Sciences Department, SATT-ValorPaca (FR) André Syrota, President, Aviesan Institute for health Technologies(FR) Garold BREIT, Executive Director, University of Manitoba (USA) 11:00-11:30 Networking Break

5 MONDAY, OCTOBER 1 st, 2012 Therapeutic Insight: "Therapeutic Insight" is a new forum of Innovation Days dedicated to industry executives to gain an enriched understanding of transformational challenges emerging across the industry and within the scientific, clinical and commercial spectra of selected diseases and technological areas. Therapeutic insight sessions will provide an overview of development and regulatory issues, as well as market dynamics and business development challenges. Those forums will be followed by selected Biotech Companies' Presenting session. 11:30-1:00 Therapeutic Insight Focus on CARDIOVASCULAR Cardiovascular disease's effects on world health and the economics of healthcare are devastating. This session will connect the "big picture" with the real world of drug development and commercialization issues. The panel will provide an analysis of standards of care and epidemiology, market dynamics, and will take a close look at trends in cardiovascular partnering deal. Pr. Faiez Zannad, Cardiologist and Prof. of Therapeutics, University of Nancy (FR) Jean-Louis Dasseux, CEO, Cerenis Therapeutics (FR) Dave Adams, Vice President Integrations & Divestitures, Medtronic (USA) 1:00-2:00 Lunch 2:00-3:30 Therapeutic Insight Focus on INFECTIOUS DISEASES This session will contribute to the on-going battle against the ever-changing infectious threats by having experts with direct experiences in the field discuss a wide variety of topics on infectious diseases. These topics will include reviews of emerging treatment of anti-infectives and vaccines in addition to subjects including portfolio value management, license revenue and patent extension strategies. Pr. Bruno Lina, Head, National Reference Centre for Influenza (FR) Dr. John A. Thomson, VP, Strategic R&D Networks, Vertex Pharmaceuticals Incorporated (USA) Luc AUJAME, Director of External Research and Development, Sanofi Pasteur (FR) 3:30-4:00 Networking break 4:00-5:00 Keynote session European bioclusters organizations: sparring partners for Innovation Globalization of research and Innovation and global competition are putting a new emphasis on the role of regional clusters and further development. This session will address the way that clusters foster Innovation in Life Sciences sector thanks to: Close collaborations between academia and industry Access to national investors Talented individuals Governmental support Through testimonials, the clusters representatives will highlight the key success ingredients that bring fruitful ecosystem to their members and particularly to young innovative companies. Patrick FAURE, Director, SATT-ValorPaca (FR) Tony JONES, Director of Business Development, One nucleus (UK) Montserrat VENDRELL, Director, Biocat (SP) Franck MOLINA, Co-founder, EUROMEDIAG (FR)

6 MONDAY, OCTOBER 1 st, :00-6:00 Keynote session Addressing biotech funding difficulties What makes a biotech company successful? For young biotechs, attracting seed and early-stage funding has become increasingly difficult in recent years although anecdotal signs of recovery are beginning to emerge. However it is still possible to identify certain characteristics that make some biotech business models more likely to succeed than others. This panel will address the strategies being employed by biotech CEOs and earlystage investors to ensure an adequately funded R&D pipeline. David Collier, CEO, Velocity Pharmaceutical Development, CMEA Capital, (USA) Alain Moussy, CEO, AB-Sciences (FR) Florent GROS, Managing Director, Novartis Venture Fund (CH) Pierre-Noel Lirsac, Director of Public Financing of the Cell Therapy Programs, LFB Group (FR) Trying to figure out the best biotech business model? This session is a great place for biotechnology companies to meet and share ideas. 6:00 Exhibit Hall Hospitality Reception

7 tuesday, OCTOBER 2 nd, :30-10:15 Keynote session Human and Social Science perspectives on Biotechnologies Organizational solutions and drivers for Innovation Human resources management is an essential criteria for success in a rapidly changing world of scientific understanding and marketplace evolution. However, the biotech industry generally does not feel that the capital produced by its employees is the most precious resource. The social organization, the enterprise culture and its values are key factors of success to translate science and innovation into medicines that make a difference. This presentation will explore successful initiatives focused on the establishment of a highly functional culture and organization. Setting-up your organization to ensure an environment of innovation, Sharing transversally across the organization and establishing a toolkit of practices that work. Jean Deregnaucourt, Executive Vice President Business Development, Institut Pasteur (FR) Christian BECHON, Director, LFB Group (FR) Claire Skentelbery, Network Manager, Council of European BioRegions (CEBR) (BE) Jacques-Bernard Taste, Biotech Finances (FR) 10:15-11:00 Closing Panel Discussion Market Access and Innovation Reverse drug development process to meet changing payer requirements? In order to launch a successful product, reimbursement needs to be taken into account far earlier in the development lifecycle than in the past. This session will focus on the R&D s role in developing products with a greater probability of market access: Developing a disease area strategy for an unmet clinical or economic need, Understanding the willingness of the public or private payer to cover a drug (cost/ differentiation), Insights for early feedback on the feasibility of market access for a developing product. Attractiveness to payers, what does this really mean? This panel will deliver provocative views on attempts to formulate recipes to develop a go-to-market strategy. Herve Lilliu, Vice President Global health Outcomes, market Access and Pricing, UCB (B) Jan Posthumus, Head of Global Market Access and Market Research, Basilea Pharmaceuticals (CH) Olivier Le Dour, Scientific officer, Research Medical program, European Commission (B) Gilles Johanet, President, Economic Committee on Health Care Products (CEPS) (FR) 11:00-11:30 Networking break 11:30-13:00 Therapeutic Insight Focus on ONCOLOGY & Personalized Medicine In this session, experienced dealmakers, pharma leaders and diagnostic development experts will explore: Leveraging key factors of success for personalized approach to oncology drug development, Predicting a changing regulatory environment and its impact on translating biomarkers to the clinic and into the marketplace, Identifying the new players emerging within the personalized medicine space (i.e., emerging companies, re-modeled companies, institutes, patient-centered social media), Understanding drivers for strategic decision making in oncology drug development. Christophe THURIEAU, VP scientific affairs, President Ipsen Innovation, Ipsen Group (FR) Pr. Bertrand Coiffier, European Institute of Lymphoma, University of Lyon, France (FR) Stephan Chalon, Head of Research & Translational Medicine Institute, Roche (CH) Dominique Bagnard, CEO, MTP Therapeutics (FR)

8 tuesday, OCTOBER 2 nd, :00-2:00 Lunch 2:00-3:30 Therapeutic Insight Focus on Central Nervous System CNS disorders represent a significant unmet medical need and societal burden and yet pose challenges for investment by the biotech and pharma Industry. Solutions will be discussed from recent scientific discoveries and from novel partnership structures with biotech companies, academic investigators, advocacy organizations and governmental authorities. David S. Goldstein, Senior Investigator and Chief, National Institutes of Health (USA) Timothy Herpin, Vice-President Strategic Partnering and Business Development, CNS and Pain, Astrazeneca (USA) Armin Giese, Center for Neuropathology and Prion Research, Ludwig-Maximilian- University, Munich (DE) 3:30-4:00 Networking break 4:00-5:00 Presenting session: Innovation Prize Finalists The Universal Biotech Innovation Prize confers visibility to promising innovations and aims at facilitating partnership between the public and private stakeholders. It is a unique opportunity to identify promising and innovative projects. The Universal Biotech Innovation Prize is open to young innovative companies and to academic researchers on: Selection criteria: search for Excellence Innovation degree Industrial Property Financing Chances of success on the market 5:00-5:30 Innovation Prize ceremony 5:30-6:00 Closing Networking break

9 1 st, 2 nd & 3 rd October 2012 Cité Internationale Universitaire of Paris, France Find out more... CONTACTS Universal Medica Group 342 Bureaux de la Colline Saint-Cloud +33 (1) Rafi Mardachti, General Manager rafi.mardachti@universalmedica.com Aurélia Ringard, Business Developer aurelia.ringard@universalmedica.com